Ricevi le ultime notizie sulle azioni ADMA Biologics con aggiornamenti su tendenze di mercato, dati finanziari e analisi di Benzinga. Rimani informato sulle performance di ADMA

Ultime notizie per

ADMA BIOLOGICS INC

ADMA Biologics

ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The segments of the company are ADMA BioManufacturing which generates maximum revenue and Plasma Collection Centres, and corporate segment. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling and packing services. The company derives maximum revenue from United States.

News

Markets

Media

Trading Ideas

ADMA

KEYS

NVCR

Il noto opinionista finanziario rivede la sua posizione su un&#39;azienda specifica, mentre altre vengono esaminate con cautela.

Jim Cramer ha cambiato idea? Ecco un titolo &#34;di nicchia&#34; che ora adora

ADMA Biologics Inc

Press Releases

ADMA Biologics to Participate in the Raymond James Institutional Investor Conference

Earnings

ADMA Biologics Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

BREAKING: Block & Leviton Investigating ADMA Biologics, Inc. for Securities Fraud Violations Following Delayed 10-K and KPMG Evaluation of Controls

ADMA Biologics Statement on Tariffs

General

ADMA Biologics Announces U.S. FDA Approval of Innovative Production Yield Enhancement Process

Global Artificial Intelligence Influence on Diabetic Retinopathy Market Expected to See Significant Growth

ADMA Biologics to Report First Quarter 2025 Financial Results on May 7, 2025

ADMA Biologics Announces First Quarter 2025 Financial Results and Provides Business Update

ADMA Biologics to Report Second Quarter 2025 Financial Results on August 6, 2025

ADMA Biologics Announces Second Quarter 2025 Financial Results and Provides Business Update

AVAI

POAI

RXRX

Ascentage Pharma Group International - American Depository Shares

Ascentage Pharma Group

ACADIA Pharmaceuticals Inc. - Common Stock

ACADIA Pharmaceuticals

Arcellx

Akero Therapeutics

Apogee Therapeutics

Apellis Pharmaceuticals, Inc. - Common Stock

Apellis Pharmaceuticals

CG Oncology

Centessa Pharmaceuticals plc - American Depositary Shares

Centessa Pharmaceuticals

GRAIL

Immunovant

Kiniksa Pharmaceuticals, Ltd. - Class A Ordinary Shares

Kiniksa Pharmaceuticals

Kymera Therapeutics

Jyong Biotech

Mirum Pharmaceuticals, Inc. - common stock

Mirum Pharmaceuticals

Mineralys Therapeutics, Inc. - Common Stock

Mineralys Therapeutics

NewAmsterdam Pharma Company N.V. - Ordinary Shares

NewAmsterdam Pharma Co

Praxis Precision Medicines, Inc. - Common Stock

Praxis Precision Medicine

Protagonist Therapeutics, Inc. - Common Stock

Protagonist Therapeutics

uniQure

Ultragenyx Pharmaceutical Inc. - Common Stock

Ultragenyx Pharmaceutical

Soleno Therapeutics

Telix Pharmaceuticals Limited - American Depositary Shares

Telix Pharmaceuticals

Viking Therapeutics

Xenon Pharmaceuticals Inc. - Common Shares

Xenon Pharmaceuticals

Zai Lab Limited - American Depositary Shares

Comments

ADMA Biologics Notizie sulle azioni

Notizie

Ultime notizie per

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO